Therapy for chronic viral hepatitis

Clinical and Investigative Medicine

Volumn 19, Issue 5, 1996, Pages 381-388

  Alvarez, Fernando ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; IMMUNOGLOBULIN; PREDNISONE; VIRUS DNA;

ABDOMINAL PAIN; ALOPECIA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DISEASE DURATION; DRUG EFFICACY; FOLLOW UP; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; PRIORITY JOURNAL; SEROCONVERSION; THROMBOCYTOPENIA; VIRUS CARRIER; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0029847151     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterologe 1990;99:805-10.
2. Hsu HY, Chang MH, Lee CY, Chen JS, Hsu HC, Chen DS. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology 1992;15:382-6.
3. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106:1000-5.
4. De Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4.
5. Bortolotti F, Jara P, Diaz C, et al. Posttransfusion and community-acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994;18:279-83.
6. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.
7. Kiyosawa K, Akahame Y, Nagata A, et al. Significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox Sanguinis 1982;43:45-52.
8. Bortolotti F, Di Marco V, Vajro P, et al. Long-term evolution of chronic delta hepatitis in children. J Pediatr 1993;122:736-8.
9. Tolentino P, Dianzani F, Zucca M, Giacchino R. Decreased interferon response by lymphocytes from children with chronic hepatitis. J Infect Dis 1975;132:459-63.
10. Ikeda T, Lever AML, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 1986;6:962-5.
11. Dianzani F, Antonelli G, Capobianchi MR. The biological basis for clinical use of Interferon. J Hepatol 1990;11:55-10.
12. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. Efficacité d'une immunothérapie par vaccination contre le virus de l'hépatite B sur la multiplication virale B. Life Sci 1993;316:688-91.
13. Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-α in children with chronic hepatitis B. Hepatology 1991;13:1035-9.
14. 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994;20:287-90.
15. Utili R, Sagnelli E, Gaeta GB, et al. Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. J Hepatol 1994;20:163-7.
16. Scotto J, Hadchouel M, Hery C, et al. Hepatitis B virus DNA in children's liver diseases: detection by blot hybridisation in liver and serum. Gut 1983;24:618-24.
17. Ruiz-Moreno M, Rua MJ, Castillo I, et al. Treatment of children with chronic hepatitis C with recombinant interferon-α: a pilot study. Hepatology 1992;16:882-5.
18. Clemente MG, Congia M, Lai ME, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123-8.
19. Inui A, Fujisawa T, Miyagawa Y, et al. Histologic activity of the liver in children with transfusion-associated chronic hepatitis C. J Hepatol 1994;21:748-53.
20. Fujisawa T, Ohkawa T, Inui A, Yokota S. Effect of interferon therapy on serum hepatitis C virus RNA levels in children with chronic hepatitis C. Int Hepatol Commun 1994;2:316-20.
21. Tiné F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized cinical trials. J Hepatol 1991;13:192-9.
22. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993;34:1714-7.
23. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
24. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-83.
25. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
26. Orito E, Mizokami M, Mizoguchi N, et al. Hepatitis C virus serotype II responds more favorably to interferon-α therapy. J Hepatol 1994;21:130-2.
27. Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-30.
28. Kakumu S, Yoshika K, Tanaka K, et al. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 1993;41:65-70.
29. Johnson Y, Lau N, Mizokami M, et al. Serum ALT: tarnished gold standard for interferon response in hepatitis C virus infection. Lancet 1993;342:1208-9.
30. Saleh MG, Tibbs CJ, Koskinas J, et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 1994;20: 1399-1404.
31. Marcellin P, Boyer N, Routeau M, Benhamou JP, Erlinger S. Retreatment with interferon-α of chronic hepatitis C virus infection. Lancet 1994;344:690-1.
32. Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994;21:199-203.
33. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995;123:32-4.
34. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993;104:1762-7.
35. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94.
36. Kay MH, Wyllie R, Deimler C, Caulfield M, Steffen R, Baetz-Greenwalt B. Alpha interferon therapy in children with chronic active hepatitis B and delta virus infection. J Pediatr 1993;123:1001-4.